User-Fee Sticker Shock? Industry Pursues Trimmed-Down MDUFA IV Proposal
This article was originally published in The Gray Sheet
Executive Summary
Device industry groups significantly pared down their review-process reform proposals for the next user-fee program at a meeting with FDA last month. To lower the price tag, they expunged more than a dozen ideas that have been raised by companies or the agency at prior meetings. But FDA sees a lot of important priorities missing in industry's latest five-point plan.
You may also be interested in...
Shuren In The Lion’s Den: Device Center Chief Defends LDT Plan At Clinical Lab Meeting, Fields Wide Array Of Questions
FDA device center Director Jeff Shuren explained and defended fine points of FDA’s proposed laboratory-developed test framework before some of his sharpest critics: members of the American Clinical Laboratory Association, who face an entirely new regulatory scheme once the LDT proposal is finalized.
FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.